Indian pharma firm Zydus Cadila (NSE: CADILAHC) has been granted approval from the US Food and Drug Administration (FDA) to market Clobetasol Propionate ointment USP, 0.05%, in the US market, the company said on Monday.
Clobetasol Propionate ointment is used in the treatment of a range of skin conditions, such as eczema, dermatitis, allergies and rashes.
The company confirmed that the ointment will be manufactured at its Ahmedabad-based facility.
It marks the latest in the Zydus group's extensive portfolio of more than 165 product approvals.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary